This article is more than 5 years old. Information may no longer be current.

VIDEO: Triplet therapy offers ‘new option’ for multiple myeloma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ORLANDO — In this video, Matthew Pianko, MD, clinical assistant professor of internal medicine at the University of Michigan’s Rogel Cancer Center, discusses a late breaking abstract on the “exciting” CANDOR study presented the ASH Annual Meeting and Exposition.

The findings indicated that the combination of carfilzomib, daratumumab and dexamethasone had better progression free survival, overall response rate and minimal residual disease negative-complete response rate among patients with multiple myeloma than the combination of carfilzomib and dexamethasone, according to Pianko.

“Carfilzomib, daratumumab and dexamethasone represent a new option for patients with relapsed/refractory multiple myeloma,” he said. – by Alaina Tedesco

Reference:

Usmani SZ, et al. Abstract LBA-6. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2019; Orlando.

Disclosure: Pianko reports no relevant financial disclosures.